Biotech
Tango Therapeutics
Tango Therapeutics raises $165M Series B at $600M valuation
$165M
Total Raised
Series B
Latest Round
2017
Founded
120+
Employees
100 Binney Street, Cambridge, MA 02142
1 min read
Quick Facts
Valuation
$600M
Latest Round Size
$165M
Latest Round Date
February 2024
Tango Therapeutics: Series B Funding Round
Tango Therapeutics has successfully raised $165M in Series B funding, reaching a valuation of $600M.
Company Overview
Cancer therapeutics discovering synthetic lethal drug targets
Funding Details
The Series B round was led by Third Rock Ventures, with participation from BVF Partners, Boxer Capital, Casdin Capital.
Company Information
- Headquarters: 100 Binney Street, Cambridge, MA 02142
- Founded: 2017
- Employees: 120+
- Category: Biotech
Investment
Tango Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Third Rock Ventures: Verified investor in Series B
- BVF Partners: Verified investor in Series B
- Boxer Capital: Verified investor in Series B
- Casdin Capital: Verified investor in Series B
Key Investors
Third Rock Ventures
Lead Investor
Verified investor in Series B
BVF Partners
Investor
Verified investor in Series B
Boxer Capital
Investor
Verified investor in Series B
Casdin Capital
Investor
Verified investor in Series B
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M